Castle Biosciences, Inc. (CSTL) vs NeoGenomics, Inc. (NEO)
Castle Biosciences, Inc. and NeoGenomics, Inc. are both Diagnostics & Research companies. NeoGenomics, Inc. is the larger, with a market value of $2.5B against $1.1B — 2.3× the size. NeoGenomics, Inc. grew revenue faster over the last twelve months: 11.2% against 3.18%. Castle Biosciences, Inc. has the higher net margin (−5.43% vs −6.77%) and the lower return on invested capital (−9.40% vs −4.20%). Across the 18 metrics below, Castle Biosciences, Inc. leads on 13 and NeoGenomics, Inc. on 5.
Valuation
Profitability
| Metric | CSTL | NEO | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 77.26% | 43.92% | 50.89% |
| Operating margin | (8.99%) | (8.93%) | (8.57%) |
| Net margin | (5.43%) | (6.77%) | (6.37%) |
| Free cash flow margin | (0.13%) | (0.69%) | 0.00% |
| Return on equity | (4.20%) | (6.33%) | (2.92%) |
| Return on assets | (3.51%) | (3.78%) | (6.71%) |
| Return on invested capital | (9.40%) | (4.20%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack